International evaluation of circumferential resection margins after rectal cancer resection: insights from the Swedish and Dutch audits
- PMID: 31696599
- PMCID: PMC7187294
- DOI: 10.1111/codi.14903
International evaluation of circumferential resection margins after rectal cancer resection: insights from the Swedish and Dutch audits
Abstract
Aim: This study aimed to determine predictive factors for the circumferential resection margin (CRM) within two northern European countries with supposed similarity in providing rectal cancer care.
Method: Data for all patients undergoing rectal resection for clinical tumour node metastasis (TNM) stage I-III rectal cancer were extracted from the Swedish ColoRectal Cancer Registry and the Dutch ColoRectal Audit (2011-2015). Separate analyses were performed for cT1-3 and cT4 stage. Predictive factors for the CRM were determined using univariable and multivariable logistic regression analyses.
Results: A total of 6444 Swedish and 12 089 Dutch patients were analysed. Over time the number of hospitals treating rectal cancer decreased from 52 to 42 in Sweden, and 82 to 79 in the Netherlands. In the Swedish population, proportions of cT4 stage (17% vs 8%), multivisceral resection (14% vs 7%) and abdominoperineal excision (APR) (37% vs 31%) were higher. The overall proportion of patients with a positive CRM (CRM+) was 7.8% in Sweden and 5.4% in the Netherlands. In both populations with cT1-3 stage disease, common independent risk factors for CRM+ were cT3, APR and multivisceral resection. No common risk factors for CRM+ in cT4 stage disease were found. An independent impact of hospital volume on CRM+ could be demonstrated for the cT1-3 Dutch population.
Conclusion: Within two northern European countries with implemented clinical auditing, rectal cancer care might potentially be improved by further optimizing the treatment of distal and locally advanced rectal cancer.
Keywords: Netherlands; Rectal neoplasms; Sweden; colorectal surgery; hospitals; surgical margin.
© 2019 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.
Conflict of interest statement
RD, DS, MPMdNtB, JWTD, MWJMW, NAWvG, WAB, PJT, AM and MW have no conflicts of interest or financial ties to disclose.
Figures


References
-
- Kanavos P, Schurer W. The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ 2010; 10(Suppl 1): 115. - PubMed
-
- Pahlman L, Bohe M, Cedermark B et al The Swedish rectal cancer registry. Br J Surg 2007; 94: 1285–92. - PubMed
-
- Kapiteijn E, Putter H, van de Velde CJ et al Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002; 89: 1142–9. - PubMed
-
- Erlandsson J, Torbjörn Holm T et al Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non‐blinded, phase 3, non‐inferiority trial. Lancet Oncol 2017; 18: 336–46. - PubMed
-
- Kapiteijn E, Marijnen CA, Nagtegaal ID et al Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 30: 638–46. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous